Should frontline Hodgkin lymphoma therapy differ based on validated genetic, immunologic, or biochemical biomarkers?

Blood Immunology & Cellular Therapy · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles